Exact Sciences (EXAS) Misses Q3 EPS by 12c, Revenue Beats, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Exact Sciences (EXAS) PT Lowered to $125 at Stifel
November 3, 2021 6:44 AM EDTStifel analyst Daniel Arias lowered the price target on Exact Sciences (NASDAQ: EXAS) to $125.00 (from $145.00) while maintaining a Buy rating.
The analyst commented, "EXAS's 3Q saw the company miss on Screening (Cologuard) revenues, and lower the outlook for 4Q - as... More
